<DOC>
	<DOCNO>NCT01788228</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability GSK Biologicals ' vaccine GSK1557484A pandemic avian ( H5N1 ) influenza adult occupational risk exposure virus .</brief_summary>
	<brief_title>Safety Tolerability Study GlaxoSmithKline ( GSK ) 1557484A Vaccine Adults Occupational Risk Influenza A ( H5N1 ) Exposure</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator comply requirement protocol . Male female adult ≥18 year age time first study vaccination . Written inform consent obtain subject . Subjects risk occupational exposure H5N1 influenza virus base exposure , potential exposure either ( ) laboratory operation live H5N1 virus , ( b ) production H5N1 vaccine , ( c ) conduct epidemiological investigation H5N1 case . Stable health status define absence health event satisfy definition serious adverse event , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within 30 day prior enrollment . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree practice adequate contraception two month follow last dose vaccine . Presence evidence neurological psychiatric diagnosis , although stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence temperature ≥ 38.0ºC ( ≥100.4ºF ) acute symptom great `` mild '' severity schedule date first vaccination . NOTE : The subject may vaccinate later date , provide symptom resolve , vaccination occurs within window specify protocol , eligibility criterion continue satisfy . Significant risk complication intramuscular injection due disorder coagulation . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . Assessment risk injection complication make context individual subject risk H5N1 virus infection . An acute evolve neurological disorder Guillain Barré Syndrome within 42 day receipt prior seasonal pandemic influenza vaccine . Administration inactive vaccine within 14 day live attenuated vaccine within 30 day first dose study vaccine . Planned administration vaccine study vaccine Day 42 . Any known suspected allergy constituent influenza vaccine component use manufacturing process study vaccine include history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result first vaccination . Lactating nursing woman . Any condition , opinion investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Occupational exposure</keyword>
	<keyword>Influenza</keyword>
	<keyword>H5N1</keyword>
</DOC>